Positive AGM Statement & Trading Update
RUA Life Sciences’ AGM statement provided tangible progress on its heart valve and vascular graft products, detail on revenue expectations and reassuring cost control since its FY 2023 results announcement. Our valuation remains at £120.3m (542p per share).RUA Contract Manufacture has announced progress with a customer funded project that assuming success, is anticipated will convert into a supply contract. This would appear to be a new customer and is in addition to building on this relationship with other customers help add to the confidence held by management that the Contract Manufacture business can double in scale.
The AGM statement also points to the group’s revenues meeting the Board’s expectations, the tight control over cash – which is ahead of management’s budget – and the positive indication of expansion in scope of a license that may double over time after this extension of an existing license.
Developments in RUA Vascular have continued with the regulatory progress and preparation for the clinical trials of its vascular graft product noted in the AGM statement, however a new shorter term revenue opportunity has been reported of the first commercial OEM sales for testing.
The upbeat narrative on RUA Structural Heart continues. RUA’s AGM statement refers to the now-completed 400 million cycle milestone, equivalent to 10 years in man and double the regulatory requirement for its composite (Elast-Eon and textile) heart valve. Its significant performance attributes could make RUA’s leaflet material an attractive slot-in for the heart valve scaffolds of other manufactures. This is the second company reference to the use of RUA’s composite Elast-Eon-coated leaflets in heart valves currently on the market. As a potential OEM supplier to other heart valve manufacturers, the AGM statement notes an approach by such a manufacturer who will conduct an evaluation.
Aortech International is an Intellectual Property (IP) holding company whose principal activity is exploiting the value of its IP and know-how.
Equity Development enables companies to become better understood and supported by investors. Since our launch in 1996 we have consistently focused on helping our clients improve their communication and relationships with both existing and potential shareholders. Our clients have come from a wide variety of sectors and domiciles, are both private and quoted and range in size from micro-cap to $multi-billions. We offer free access to company research notes written by experienced analysts. These notes include detailed forecasts, financial models and a fair value. We host regular Private Investor Forums at which investors have the opportunity to hear company directors present, and to ask questions. These are free to attend. We broadcast live Webinars with company management that include active Q&A. We also make the recordings available online. We arrange face to face meetings between private investors and company management. We are active users of Twitter, commenting daily on company news, share price moves, Directors’ Dealings, Equity Development Research Notes & Events.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.